DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Price Performance

DRRX stock opened at $0.98 on Tuesday. The company has a market capitalization of $30.42 million, a PE ratio of -1.61 and a beta of 1.13. DURECT has a 12 month low of $0.48 and a 12 month high of $1.88. The firm’s 50-day moving average is $1.33 and its 200 day moving average is $1.37.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC increased its position in DURECT by 41.3% during the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares during the period. Geode Capital Management LLC increased its position in DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 14,658 shares during the period. Accredited Investors Inc. bought a new stake in shares of DURECT in the 2nd quarter valued at about $113,000. Finally, Richmond Brothers Inc. boosted its holdings in shares of DURECT by 39.5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after buying an additional 303,670 shares in the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.